ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for endometrial cancer: targeted therapy trial opens
Disease control Recruiting nowThis study tests a new drug called ACR-368, given alone or with a low dose of chemotherapy, in people with endometrial cancer. The goal is to see if the drug can shrink tumors. About 400 participants will join this phase 2 trial to check safety and effectiveness.
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control Recruiting nowThis study tests a new drug, APL-5125, in about 100 adults with advanced solid tumors like colorectal, pancreatic, and breast cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The trial has two pha…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Immunotherapy duo shows promise against tough uterine cancer
Disease control Recruiting nowThis study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (called dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against one drug alone (nivolumab) to see which shrinks tumors better. About …
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:56 UTC